Overview

Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

Status:
Completed

Trial end date:
2021-06-10

Target enrollment:

Participant gender:

Summary

Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.

Phase:

Phase 1

Details

Lead Sponsor:

University of Karachi

Collaborators:

Center for Bioequivalence Studies and Clinical Research
SAMI Pharmaceutical, Karachi Pakistan

Treatments:

Moxifloxacin